PL1806136T3 - Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego - Google Patents

Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego

Info

Publication number
PL1806136T3
PL1806136T3 PL05790245T PL05790245T PL1806136T3 PL 1806136 T3 PL1806136 T3 PL 1806136T3 PL 05790245 T PL05790245 T PL 05790245T PL 05790245 T PL05790245 T PL 05790245T PL 1806136 T3 PL1806136 T3 PL 1806136T3
Authority
PL
Poland
Prior art keywords
group
prevention
transition
optionally substituted
medicinal composition
Prior art date
Application number
PL05790245T
Other languages
English (en)
Inventor
Yoshio Okubo
Tomoji Shimizu
Nobuhiko Arai
Yasuhiro Omori
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36142692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1806136(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of PL1806136T3 publication Critical patent/PL1806136T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Indole Compounds (AREA)
PL05790245T 2004-10-06 2005-10-04 Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego PL1806136T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004294358 2004-10-06
JP2005160843 2005-06-01
PCT/JP2005/018356 WO2006038619A1 (ja) 2004-10-06 2005-10-04 前立腺肥大症に対する手術療法への移行予防用医薬組成物
EP05790245A EP1806136B1 (en) 2004-10-06 2005-10-04 Medicinal composition for prevention of transition to operative treatment for prostatic hypertrophy

Publications (1)

Publication Number Publication Date
PL1806136T3 true PL1806136T3 (pl) 2012-04-30

Family

ID=36142692

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05790245T PL1806136T3 (pl) 2004-10-06 2005-10-04 Kompozycja medyczna do zapobiegania przejściu na leczenie operacyjne łagodnego rozrostu gruczołu krokowego

Country Status (12)

Country Link
US (1) US20080090893A1 (pl)
EP (1) EP1806136B1 (pl)
JP (1) JPWO2006038619A1 (pl)
KR (1) KR20070059152A (pl)
AT (1) ATE535242T1 (pl)
CA (1) CA2582045C (pl)
ES (1) ES2378240T3 (pl)
PL (1) PL1806136T3 (pl)
PT (1) PT1806136E (pl)
SI (1) SI1806136T1 (pl)
TW (1) TWI377058B (pl)
WO (1) WO2006038619A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106536A1 (en) * 2007-02-28 2008-09-04 Kissei Pharmaceuticals Co., Ltd. Use of silodosin in a once daily administration for treating benign prostatic hyperplasia
WO2009013846A1 (ja) * 2007-07-20 2009-01-29 Astellas Pharma Inc. 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
EP2181707A1 (en) * 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
JP5965902B2 (ja) * 2010-06-28 2016-08-10 ラティオファルム ゲー・エム・ベー・ハー シロドシン−シクロデキストリン包接化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999015202A1 (fr) * 1997-09-22 1999-04-01 Kissei Pharmaceutical Co., Ltd. Medicaments contre la dysurie resultant d'une hypertrophie de la prostate
PT1293198E (pt) * 2001-09-14 2005-06-30 Kissei Pharmaceutical Co Lda Dispositivo de administracao transdermica para o tratamento de patologias do tracto urinario
US20030225079A1 (en) * 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
CH698144B1 (fr) * 2003-09-24 2009-05-29 Bioxell Spa Analogue de la vitamine D3
WO2005085195A1 (ja) * 2004-03-05 2005-09-15 Kissei Pharmaceutical Co., Ltd. 神経障害に伴う過活動膀胱の予防または治療用医薬組成物

Also Published As

Publication number Publication date
EP1806136B1 (en) 2011-11-30
TW200626143A (en) 2006-08-01
SI1806136T1 (sl) 2012-03-30
TWI377058B (en) 2012-11-21
PT1806136E (pt) 2012-03-08
US20080090893A1 (en) 2008-04-17
JPWO2006038619A1 (ja) 2008-05-15
KR20070059152A (ko) 2007-06-11
EP1806136A1 (en) 2007-07-11
CA2582045A1 (en) 2006-04-13
ATE535242T1 (de) 2011-12-15
WO2006038619A1 (ja) 2006-04-13
ES2378240T3 (es) 2012-04-10
CA2582045C (en) 2013-10-22
EP1806136A4 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
NO20050016L (no) Difenylazetidinonderivater for behandling av forstyrrelser i lipid metabolismen
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
DK1697370T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
NO20051527D0 (no) 3-(sulfonamidoetyl) -indol-derivater for anvendelse som glukocorticoid-mimetica ved behandling av inflammatoriske, allergiske og proliferative sykdommer.
UA84146C2 (ru) Амиды пирролопиридин-2-карбоновой кислоты как ингибиторы гликогенфосфорилазы, способ их получения, фармацевтическая композиция и их применение как терапевтических агентов для лечения заболеваний
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
WO2001064642A3 (en) Benzamides and related inhibitors of factor xa
PT1263730E (pt) Derivados amina para o tratamento de apoptose
PT1452524E (pt) Derivado de 2-oxo-1-pirrolidina e suas utilizações farmacêuticas
JO2371B1 (en) 4-phenyl-pyridine derivatives
WO2006011050A3 (en) Pyridine derivatives
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
NO20015172L (no) 1-metyl-erytromycin-derivater
SE0402925D0 (sv) Novel Compounds
HK1053833A1 (zh) 取代苯基法呢基转移酶抑制剂
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen